1662 results for "LSD"
Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects
Neuropsychopharmacology – October 15, 2020
Summary
Lysergic acid diethylamide's (LSD) full psychedelic effects are primarily mediated by serotonin 5-HT2A receptor activation. A **crossover study** of 16 healthy subjects, using **placebo** and varied doses of this **alkaloid**, explored its **pharmacology** and **pharmacokinetics**. While subjective "good effects" plateaued at 100 µg, anxiety and ego dissolution increased at 200 µg, with effects lasting 6.7 to 11 hours. **Ketanserin** effectively blocked the 200 µg LSD response, confirming this **neurotransmitter receptor influence on behavior**. These **drug studies** inform **medicine** and **psychology**, guiding optimal **psychedelics** dosing.
Abstract
Abstract Growing interest has been seen in using lysergic acid diethylamide (LSD) in psychiatric research and therapy. However, no modern studies h...
Past-Year Lysergic Acid Diethylamide Use in United States Sexual Minorities from 2015 to 2019
Psychedelic Medicine – December 30, 2025
Summary
LGB individuals exhibited a staggering 106% increase in past-year lysergic acid diethylamide (LSD) use from 2015 to 2019, significantly outpacing the 43% rise among heterosexuals. Representing about 5% of the sample, LGB individuals were 3.3 to 4.4 times more likely to use LSD compared to their heterosexual counterparts. Unique factors influencing LSD use included poverty and marital status for heterosexuals, emphasizing the need for tailored harm reduction strategies that consider sexual identity in psychedelic research and mental health contexts.
Abstract
Objective: This study aimed to characterize changes in estimated past-year lysergic acid diethylamide (LSD) use among sexual minorities in the Unit...
A Novel Stability Indicating High Performance Liquid Chromatography Method for Lysergic Acid Diethylamide Quantification: From Microdosing Applications to Broader Analytical Use.
Journal of chromatographic science – November 15, 2025
Summary
Many microdosing LSD users might be taking vastly different doses than intended. A robust new method was developed to precisely quantify lysergic acid diethylamide, even separating it from degradation products. This high-performance liquid chromatography (HPLC) technique was rigorously validated, proving effective under stress. Applied to community samples, a significant discrepancy emerged between user-estimated and actual LSD levels. This advancement offers crucial tools for safety and quality control in both clinical and illicit LSD formulations, underscoring risks of unregulated products.
Abstract
With the rising interest in therapeutic potential of microdosing lysergic acid diethylamide (LSD), accurate quantification and stability analysis a...
The Pharmacology of Lysergic Acid Diethylamide: A Review
CNS Neuroscience & Therapeutics – November 11, 2008
Summary
LSD, synthesized in 1938, has generated nearly 10,000 scientific papers exploring its complex pharmacology and effects on consciousness. Initially used for psychiatric research, it became an illegal substance by the mid-1960s. Despite its controversial history, recent interest has surged in its potential therapeutic applications, particularly for cluster headaches and terminal illness. While LSD is generally well-tolerated in controlled settings, uncontrolled use can lead to complications. This renewed focus highlights the need for careful study of its influence on neurotransmitter systems and behavior.
Abstract
Lysergic acid diethylamide (LSD) was synthesized in 1938 and its psychoactive effects discovered in 1943. It was used during the 1950s and 1960s as...
A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers
Journal of Psychopharmacology – August 25, 2020
Summary
A dose of 20 µg of Lysergic acid diethylamide (LSD) significantly enhanced pain tolerance during a Cold Pressor Test, allowing participants to withstand cold water for longer while reducing their perceived pain and discomfort. In a study involving 24 healthy volunteers, this low dose produced noticeable analgesic effects without inducing profound mind-altering experiences. While LSD slightly increased blood pressure and levels of anxiety and dissociation, it showcased potential as a safe pain management option, inviting further exploration in clinical settings.
Abstract
Background: Lysergic acid diethylamide (LSD) is an ergot alkaloid derivative with psychedelic properties that has been implicated in the management...
The detection and prevention of unintentional consumption of DOx and 25x‐NBOMe at Portugal's Boom Festival
Human Psychopharmacology Clinical and Experimental – May 01, 2017
Summary
At Portugal's Boom Festival in 2014, only 67.3% of samples labeled as LSD actually contained the substance. Among the 245 tested samples, 24.1% included other psychoactive substances, with 11.4% being derivatives of 2,5-dimethoxyamphetamine. Alarmingly, 74.2% of users who received unexpected results did not intend to consume what they thought was LSD. After alerts were issued, the demand for drug testing surged compared to the previous festival in 2012, highlighting the critical role of drug-checking services in preventing unintentional consumption.
Abstract
Abstract Objective This paper describes the misrepresentation of LSD at Portugal's Boom Festival 2014 and the prevention of unintentional consumpti...
Lysergic acid diethylamide stimulates cardiac human H2 histamine and cardiac human 5-HT4-serotonin receptors.
Naunyn-Schmiedeberg's archives of pharmacology – January 01, 2024
Summary
New research reveals unexpected effects of lysergic acid diethylamide (LSD) on heart function through two distinct receptor systems. The drug increases both heart rate and contractile force by activating H2-histamine and serotonin receptors in cardiac tissue. These findings from human heart samples help explain LSD's complex effects on cardiovascular function.
Abstract
Lysergic acid diethylamide (LSD) is an artificial hallucinogenic drug. Thus, we hypothesized that LSD might act 5-HT4 serotonin receptors and/or H2...
Hallucinogen use among young adults ages 19–30 in the United States: Changes from 2018 to 2021
Addiction – June 07, 2023
Summary
Non-LSD hallucinogen use, including psilocybin, doubled among young adults (19-30) in the US, rising from 3.4% in 2018 to 6.6% in 2021. This longitudinal cohort study of 11,304 individuals found Lysergic acid diethylamide (LSD) use remained stable. An odds ratio of 1.86 (95% confidence interval 1.52–2.26) revealed males had higher odds of non-LSD hallucinogen use. As interest in psychedelics for medicine grows, understanding these trends in psychology and drug studies is crucial.
Abstract
Abstract Background and aims Given the shifting landscape of hallucinogen use, particularly with increased therapeutic use, understanding current c...
Synthesis and analytical characterization of 1-(2-thienoyl)-6-allyl-nor-d-lysergic acid diethylamide (1T-AL-LAD).
Drug testing and analysis – April 01, 2025
Summary
Scientists have identified a new variant of lysergamide emerging in recreational drug markets. Through chemical synthesis and analysis, researchers confirmed that products sold as "1D-AL-LAD" actually contain a different compound called 1T-AL-LAD. This new psychoactive substance has distinct chemical properties that make it identifiable in lab testing, helping authorities better monitor and identify these compounds.
Abstract
Lysergic acid diethylamide (LSD) analogs have emerged as new psychoactive substances (NPS) since the mid-2010s, and new compounds continue to emerg...
Psychedelics: The New Kid on the Block
Annals of Indian Psychiatry – January 01, 2024
Summary
Remarkably, 80% of 51 cancer patients maintained significant reductions in depression and anxiety six months after high-dose psilocybin. These psychedelics, studied extensively in drug studies and psychology, alter perception and consciousness, potentially inspiring new perspectives akin to art. Biochemical analysis (fMRI/EEG) reveals they increase global functional connectivity by reconfiguring the brain's functional "blocks." From chemical synthesis of alkaloids, these substances show promise for depression, addiction, and anxiety, revolutionizing psychopharmacology.
Abstract
HISTORY In the early part of twentieth century, these molecules were known as psychotomimetics, meaning that they create a state similar to psychos...
Evidence for a central 5‐hydroxytryptamine receptor stimulation by lysergic acid diethylamide
British Journal of Pharmacology – September 01, 1968
Summary
LSD significantly stimulates central 5-HT receptors, producing effects similar to the 5-HT precursor 5-hydroxytryptophan in rat spinal cord and brain. In a study involving various biochemical techniques, LSD reduced the turnover rate of brain and spinal cord 5-HT, while accelerating noradrenaline turnover. These effects were dose- and time-dependent, with no impact observed from LSD analogues like 2-bromo-LSD. The reduction in 5-HT turnover may stem from feedback mechanisms triggered by direct receptor stimulation, highlighting LSD's complex interaction with neurotransmitter systems.
Abstract
Lysergic acid diethylamide (LSD) and the 5‐hydroxytryptamine (5‐HT) precursor, 5‐hydroxytryptophan produced similar functional effects in rat spina...
Use of Lysergic Acid Diethylamide by Major Depression Status.
JAMA psychiatry – January 01, 2024
Summary
Recent data reveals a striking trend: LSD use among adults with depression tripled from 2008 to 2019, rising from 0.5% to 1.8%. This increase was notably higher than among those without depression. Young adults under 35 and those with lower incomes showed the most significant uptick. The findings suggest growing interest in psychedelics among people seeking alternative approaches to mental health treatment.
Abstract
Renewed interest in the clinical potential of hallucinogens may lead people with depression to a generally more positive view of the use of lysergi...
Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably?
Psychedelic medicine (New Rochelle, N.Y.) – June 01, 2024
Summary
Americans' perception of LSD's risks has shifted significantly, with those viewing the psychedelic as "greatly risky" dropping from 70.5% to 64.8% between 2015-2019. Analysis of National Survey on Drug Use and Health data reveals younger, more educated individuals tend to view lysergic acid as less dangerous. However, certain groups, including Black and Hispanic respondents, maintain higher risk perceptions.
Abstract
Though lysergic acid diethylamide (LSD) use is rising in the United States amid expanding research into the therapeutic potential of psychedelics, ...
Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine.
Molecular psychiatry – April 01, 2025
Summary
Psychedelics and stimulants reshape brain networks differently, with LSD showing unique effects on the brain's "default mode" - regions active when we're lost in thought. This research tracked brain connectivity changes in 28 healthy volunteers after taking LSD, MDMA, or amphetamine. While all substances altered brain network communication, LSD stood out by increasing connectivity between the brain's command centers while reducing it in visual areas. MDMA and amphetamine showed overlapping but distinct patterns, suggesting each substance uniquely influences how brain regions talk to each other.
Abstract
Psychedelics have recently attracted significant attention for their potential to mitigate symptoms associated with various psychiatric disorders. ...
Author response: Self-blinding citizen science to explore psychedelic microdosing
OpenAlex – December 11, 2020
Summary
Microdosing psychedelics like psilocybin offers no unique psychological benefits beyond expectation, a large clinical trial suggests. This self-blinding study, involving 191 participants over four weeks, found significant improvements in mood and anxiety for both microdose and placebo groups. Acute hallucinogen effects were observed but linked to participants breaking blind. This challenges anecdotal claims popular in clinical psychology, highlighting the potent placebo effect in medicine and addiction treatment. Findings influence future pharmacology, psychiatry, and drug studies concerning chemical synthesis.
Abstract
Article Figures and data Abstract eLife digest Introduction Materials and methods Results Discussion Appendix 1 Data availability References Decisi...
Tags
Effect of -NBOMe Compounds on Sensorimotor, Motor, and Prepulse Inhibition Responses in Mice in Comparison With the 2C Analogs and Lysergic Acid Diethylamide: From Preclinical Evidence to Forensic Implication in Driving Under the Influence of Drugs.
Frontiers in psychiatry – January 01, 2022
Summary
Psychedelic phenethylamines, like -NBOMe and 2C compounds, significantly impair sensorimotor skills and pre-pulse inhibition, sometimes more profoundly than LSD. Halogenated -NBOMe derivatives proved more potent than 2C compounds and LSD in altering visual/acoustic responses and reaction time. These novel psychoactive substances directly affect motor responses, raising serious public health concerns regarding DUID and tasks demanding precise sensorimotor coordination.
Abstract
In the last decade, the market for new psychoactive substances has been enriched by numerous psychedelic phenethylamines, which mimic the psychoact...
THE PRESERVATION OF SUBSTANCE P BY LYSERGIC ACID DIETHYLAMIDE
British Journal of Pharmacology and Chemotherapy – September 01, 1957
Summary
LSD significantly enhanced the guinea pig ileum's response to substance P, while showing no effect on histamine. In experiments, LSD inhibited the breakdown of substance P in brain extracts, a process unaffected by chymotrypsin. Notably, substances like morphine and mescaline did not replicate this effect. The presence of 2 bromo-LSD counteracted LSD's inhibition of substance P degradation. These findings suggest a potential link between LSD’s unique pharmacological actions and its influence on chemical reactions involving substance P in the brain.
Abstract
Lysergic acid diethylamide (LSD) potentiated the response of guinea‐pig ileum to substance P but not to histamine. It also inhibited the disappeara...
Pharmacokinetics and pharmacodynamics of sublingual microdosed lysergic acid diethylamide in healthy adult volunteers.
Journal of psychopharmacology (Oxford, England) – April 18, 2025
Summary
A groundbreaking study reveals that microdosing LSD produces measurable effects in the body even at very low doses. Scientists tracked how the psychedelic compound moves through and affects the body (pharmacokinetics and pharmacodynamics) when taken sublingually. Results showed peak concentrations occur within 90 minutes, with subtle physiological changes lasting about 3 hours.
Abstract
Microdosing is the practice of taking psychedelic drugs at doses that produce no or minimal perceptible subjective or behavioural effects. This stu...
Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.
Experimental and Clinical Psychopharmacology – January 10, 2019
Summary
Repeated dosing with the hallucinogen LSD significantly reduced depression-like effects in rats, offering a promising avenue for medicine. These psychedelics, including mescaline and psilocybin, are potent 5-HT2A receptor agonists. However, drug studies revealed their pharmacology shows weak abuse potential, unlike methamphetamine. This research highlights complex neurotransmitter receptor influence on behavior, a field explored in psychology, distinct from studies on, for example, nicotinic acetylcholine receptors.
Abstract
The prototype 5-HT2A receptor agonist hallucinogens LSD, mescaline, and psilocybin are classified as Schedule 1 drugs of abuse by the U.S. Drug Enf...
Steric and Electronic Relationships among Some Hallucinogenic Compounds
Proceedings of the National Academy of Sciences – September 01, 1970
Summary
Hallucinogenic compounds like LSD, indolcalkylamines, and methoxylated amphetamines share key structural features that enhance their psychoactive effects. Analyzing 150 compounds revealed that the aromatic benzene ring and specific nitrogen atoms are crucial for binding to neurotransmitter receptors. The interaction between these compounds and receptors may involve complex formations, influencing behavior. Notably, correlations show that hallucinogenic potency aligns with the energy of molecular orbitals, underscoring the significance of chemical structure in psychedelic activity.
Abstract
Stereochemical considerations and total valence electron calculations suggest congruities among the ostensibly dissimilar hallucinogenic compounds,...
B-302 Psychedelics and Dissociative Anesthetics: Concentrations in Suspected Impaired Driving Investigations, 2024
Clinical Chemistry – October 01, 2025
Summary
In 2024, psychedelic and dissociative drugs were detected in 328 suspected driving under the influence cases. Notably, phencyclidine (PCP) was found in 220 instances, while MDMA appeared in 81 cases. Ketamine, LSD, and psilocin were also present but in fewer samples (22, 2, and 5 respectively). Concentrations varied widely: ketamine averaged 272 ng/mL, MDMA 124 ng/mL, and PCP 50 ng/mL. These findings highlight the significant risks associated with impaired cognitive and motor functions when using these substances, particularly for activities like driving.
Abstract
Abstract Background Psychedelic and dissociative drugs, including psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (...
Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase)
Psychiatry Research – December 29, 2025
Summary
Lysergic acid diethylamide (LSD) and MDMA (Ecstasy) carry significant risks for substance abuse and addiction, a global pharmacovigilance analysis reveals. This exploratory research on 2056 adverse effect reports (1573 MDMA, 394 LSD, 56 Psilocybin, 15 Mescaline) found psychiatric issues most common. LSD showed 215-fold increased odds for substance dependence, and MDMA 129-fold for substance use disorder, versus acetaminophen. Overdoses were rare (1.1-1.7%). This informs medicine and psychiatry on recreational drug safety, particularly for hallucinogens.
Abstract
Psychedelic use has greatly increased within clinical and recreational settings over recent years. While demonstrating a favorable safety profile w...
Lysergic Acid Diethylamide and Psilocybin for the Management of Patients with Persistent Pain: a Potential Role?
Pain Management – May 01, 2018
Summary
Psilocybin and Lysergic acid diethylamide (LSD) are emerging as significant tools in Psychiatry, particularly for managing distress. These hallucinogens show considerable promise in alleviating anxiety and depression associated with life-threatening illnesses. A review of 7 studies (323 participants) on LSD and 3 studies (92 participants) on psilocybin revealed their benefits. Administered professionally, these substances are generally safe. Clinical psychology is now exploring their potential as medicine for persistent pain, given their interaction with nociception pathways, representing a new frontier in Psychedelics and Drug Studies.
Abstract
Recently, there has been interest in lysergic acid diethylamide (LSD) and psilocybin for depression, anxiety and fear of death in terminal illness....
Liquid chromatography-tandem mass spectrometry method for the simultaneous analysis of multiple hallucinogens, chlorpheniramine, ketamine, ritalinic acid, and metabolites, in urine.
Journal of analytical toxicology – October 01, 2007
Summary
Imagine detecting minute traces of multiple substances in urine with unprecedented precision. Researchers have developed a highly sensitive method to simultaneously identify various hallucinogens, ketamine, chlorpheniramine, and their breakdown products. Using advanced liquid chromatography and mass spectrometry after efficient sample preparation, the technique precisely measures these compounds. It boasts excellent accuracy, detecting LSD at just 0.05 ng/mL, and efficiently extracts over 87% of target compounds. This robust analytical tool offers a reliable way to detect these substances in human samples.
Abstract
A validated method for the simultaneous analysis of multiple hallucinogens, chlorpheniramine, ketamine, ritalinic acid, and several metabolites is ...
Neuropsychological Functioning in Users of Serotonergic Psychedelics – A Systematic Review and Meta-Analysis
Frontiers in Pharmacology – September 16, 2021
Summary
Ayahuasca use may enhance executive cognition, a compelling finding from a systematic review and meta-analysis of 13 studies (N=539) identified via databases like MEDLINE. This neuropsychology research explored serotonergic hallucinogens, including psilocybin and LSD, which influence neurotransmitter receptors. No uniform cognitive impairment emerged; instead, distinct psychological profiles appeared. A meta-analysis of 5 studies (n=352) showed ayahuasca users performed better on a Stroop task, while LSD users (n=42) exhibited reduced executive functioning. This informs clinical psychology, medicine, and psychiatry regarding these chemically diverse psychedelics.
Abstract
Background: Serotonergic psychedelics (SPs) like LSD, psilocybin, DMT, and mescaline are a heterogeneous group of substances that share agonism at ...
Adverse consequences of lysergic acid diethylamide
Addiction – October 01, 1993
Summary
LSD use is rising among young people, even as the use of other substances declines. Among users, 15% reported panic reactions, while prolonged schizoaffective psychoses were noted in 10% of cases. Additionally, post-hallucinogen perceptual disorder can last up to five years for some individuals. Although concerns about genetic disorders from hallucinogens are unfounded, evidence indicates that vulnerable individuals may experience lasting psychopathology due to LSD. A potential long-term molecular mechanism behind these adverse effects is suggested, highlighting the need for caution in psychedelic use.
Abstract
Abstract The continued endemic use of hallucinogenic drugs, and of LSD in particular, raises concern regarding their short and long term adverse co...
Psychedelic-like effects induced by 2,5-dimethoxy-4-iodoamphetamine, lysergic acid diethylamide, and psilocybin in male and female C57BL/6J mice.
Psychopharmacology – May 17, 2025
Summary
Female mice show stronger responses to classic psychedelics like LSD and psilocybin, revealing important sex-based differences in how these compounds affect the brain. Scientists tracked the distinctive head twitch response - a reliable marker of psychedelic activity linked to 5-HT2A receptor activation. While both male and female mice reacted similarly to low doses, females displayed notably more intense responses at higher doses across all tested psychedelics.
Abstract
The head twitch response (HTR) is a spontaneously occurring behavior in mice that is increased in frequency by serotonergic psychedelics. The mouse...
Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.
The Cochrane database of systematic reviews – September 12, 2024
Summary
Promising results show that carefully supervised psychedelic therapy may offer relief for patients facing life-threatening illnesses. Analysis of 6 clinical trials found that psilocybin and LSD sessions, combined with therapeutic support, reduced anxiety and depression symptoms in 140 participants. While side effects were generally mild and temporary, these treatments showed potential for easing emotional distress in seriously ill patients.
Abstract
Psychedelic-assisted therapy refers to a group of therapeutic practices involving psychedelics taken under therapeutic supervision from physicians,...
The relationship between cryptomarket drug purchase, social networks and adverse drug events: A cross-sectional study.
The International journal on drug policy – January 01, 2024
Summary
Online drug purchases through cryptomarkets are linked to higher rates of adverse drug events, particularly among solo users. Analysis of 23,000+ respondents shows that people buying drugs through digital marketplaces were more likely to use alone, without social networks for support. While overall medical incidents remained low (5.2%), cryptomarket buyers faced notably higher risks with cocaine and LSD compared to those who obtained drugs through traditional means.
Abstract
Drug use and trading are typically social activities; however, supply through cryptomarkets can occur without any in-person social contact. People ...
Acute but not long-lasting antidepressant-like effect of psilocybin in differential reinforcement of low-rate 72 schedule in rats
Journal of Psychopharmacology – October 16, 2023
Summary
Psilocybin, an alkaloid hallucinogen, delivered an immediate antidepressant-like effect in rats, a key finding for medicine. Administered at 1 mg/kg over three days, this psychedelic significantly improved reinforcement efficiency in a differential reinforcement task. However, neither psilocybin nor LSD (0.08 mg/kg) showed sustained antidepressant benefits up to four weeks later, challenging assumptions in pharmacology and drug studies, including those on chemical synthesis. This psychology experiment illuminates the complex neurotransmitter receptor influence on behavior.
Abstract
Background: In clinical studies, psychedelics including psilocybin and D-lysergic acid diethylamide (LSD) demonstrate rapid and persistent antidepr...
The association between naturalistic use of psychedelics and co-occurring substance use disorders
Frontiers in Psychiatry – January 10, 2023
Summary
Peyote or Mescaline, a classic hallucinogen, shows promise in medicine for substance abuse. Among 56,276 participants, prior use of peyote/mescaline was associated with 32% lower odds (odds ratio = 0.68) of past-year substance dependence or abuse compared to non-users. This contrasts with LSD and Psilocybin, where past use was linked to increased odds. Clinical psychology and psychiatry examine how these psychedelics, through chemical synthesis and alkaloids, impact addiction. Biochemical analysis techniques could further differentiate these effects in drug studies.
Abstract
Objective Classic psychedelics (LSD, psilocybin, and peyote/mescaline) have been used to support addiction treatment in a variety of contexts rangi...
Pharmacological characterisation of psilocybin and 5-MeO-DMT discriminative cues in the rat and their translational value for identifying novel psychedelics
Journal of Psychopharmacology – August 27, 2025
Summary
Psilocybin exposures causing perceptual effects in humans align remarkably with those eliciting similar responses in rats (5–52 ng/mL plasma). This demonstrates the translational value for Psychedelics and Drug Studies. Two cohorts of male Sprague-Dawley rats were used to understand the Neuroscience of these hallucinogens. Biochemical Analysis shows these chemical alkaloids primarily act via 5-HT2A receptors. While higher DMT/LSD plasma exposures were needed in rats, their temporal profiles (LSD > psilocybin) matched human psychological experience, enhancing our understanding of their Pharmacology.
Abstract
Background and aims: Drug discrimination procedures have made important contributions to the pre-clinical investigation of psychedelic drugs, such ...
The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series
Cephalalgia – March 26, 2010
Summary
Standard medicine often fails the 0.1% of people with severe cluster headache, making new pain management crucial. An internet survey of 53 patients claimed Lysergic acid diethylamide (LSD) and psilocybin, both hallucinogen psychedelics, offer superior relief. To overcome these drugs' undesirable properties, a non-hallucinogenic Lysergic acid analog, BOL-148, is being explored. Previous drug studies in over 300 subjects confirm BOL-148 is non-toxic, presenting a promising direction in psychiatry and Migraine and Headache Studies.
Abstract
Cluster headache (CH) is a stereotyped primary headache characterized by strictly unilateral severe orbital or periorbital pain and categorized as ...
Psychedelics: A new era of treatment?
European Psychiatry – April 01, 2021
Summary
Psychedelics like psilocybin, mescaline, and lysergic acid diethylamide (LSD) are showing remarkable promise in psychiatry and psychology. These hallucinogens, including ayahuasca, influence neurotransmitter receptors through their chemical synthesis and alkaloids. Neuroscience and drug studies confirm their therapeutic potential for anxiety and mood disorders: controlled trials observed significant reductions in anxiety and depression for cancer patients, and lessened alcohol/tobacco dependence, marking a significant shift in psychedelic medicine.
Abstract
Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have a...
Acute Lysergic Acid Diethylamide Does Not Influence Reward-Driven Decision Making of C57BL/6 Mice in the Iowa Gambling Task
Frontiers in Pharmacology – December 03, 2020
Summary
Remarkably, mice can still make reward-driven decisions even after receiving a hallucinogen like Lysergic acid diethylamide (LSD). In a Psychology and Neuroscience investigation, 15 mice performed an Iowa gambling task. Doses of this Lysergic acid-derived psychedelic (0.025-0.2 mg/kg) had no effect on their choices. Even the highest dose (0.4 mg/kg) did not impair choosing profitable options. However, Amphetamine (2.0 mg/kg) significantly hindered correct choices. This Pharmacology and Medicine insight into Serotonin Agonist influence on behavior from Chemical synthesis and alkaloids informs Drug Studies.
Abstract
While interest in psychedelic drugs in the fields of psychiatry and neuroscience has re-emerged in recent last decades, the general understanding o...
Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial.
Biological psychiatry – September 15, 2023
Summary
Small doses of LSD taken every three days improved daily well-being, creativity, and mood in healthy volunteers. In this home-based trial, participants who microdosed reported feeling more connected, energetic, and happy on dosing days, though some experienced anxiety. While these mood boosts were temporary, the study shows LSD microdosing is generally safe and can enhance daily life.
Abstract
Microdosing psychedelic drugs is a widespread social phenomenon with diverse benefits claimed for mood and cognition. Randomized controlled trials ...
Effective Connectivity of Functionally Anticorrelated Networks Under Lysergic Acid Diethylamide.
Biological psychiatry – February 01, 2023
Summary
LSD's profound ability to alter self-perception stems from its unique impact on brain network communication. Research shows the psychedelic disrupts normal boundaries between brain networks that typically maintain our sense of self. Using advanced brain imaging, scientists found LSD transforms inhibitory connections between key neural networks into excitatory ones, particularly affecting how attention-directing systems interact. This may explain the ego dissolution experience many report during psychedelic states.
Abstract
Classic psychedelic-induced ego dissolution involves a shift in the sense of self and a blurring of the boundary between the self and the world. A ...
[Salvia divinorum--representation of a new drug in the Internet].
Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) – May 01, 2006
Summary
The internet acts as an early warning system for new drug trends, often before they appear in official medical texts. An investigation compared online portrayals of Salvia divinorum, a lesser-known hallucinogen, with cannabis and LSD on German websites. Analyzing the top 100 sites for each, researchers found Salvia was actively sold on 29% of its sites, unlike cannabis or LSD. Salvia-related sites also showed a strong drug-friendly attitude (64%). Official information was rare for Salvia. This highlights the internet's crucial role in identifying emerging substance use patterns, allowing public health systems to respond proactively.
Abstract
The German pages of the Internet were searched for the presence of the hallucinogenic herbal drug Salvia divinorum, which is not dealt with in curr...
Serotonin-Sensitive Adenylate Cyclase in Neural Tissue and Its Similarity to the Serotonin Receptor: A Possible Site of Action of Lysergic Acid Diethylamide
Proceedings of the National Academy of Sciences – March 01, 1974
Summary
Low concentrations of serotonin activate a specific adenylate cyclase in insect nervous systems, crucial for neurotransmission. When tested, extremely low doses of LSD and cyproheptadine inhibited this activation, with LSD showing a strong effect at just 5 nM. This competitive inhibition suggests that the serotonin receptor closely interacts with the adenylate cyclase, influencing behavior and physiological responses. These findings highlight how psychedelics like LSD may affect serotonin pathways, providing insights into the biochemical mechanisms underlying serotonergic activity and potential therapeutic applications.
Abstract
An adenylate cyclase (EC 4.6.1.1) that is activated specifically by low concentrations of serotonin has been identified in homogenates of the thora...
Lysergic acid diethylamide pretreatment prolongs brain-stimulation induced neural activity changes
OpenAlex – December 19, 2025
Summary
LSD pretreatment significantly enhances brain activity changes, leading to longer-lasting effects compared to saline. In a study involving 24 rats, those given LSD before targeted electrical stimulation of the medial prefrontal cortex exhibited greater alterations in neural activity. Specifically, the combination of LSD and stimulation activated the mTOR signaling pathway and modified perineuronal net integrity. These findings suggest that psychedelic-assisted brain stimulation could improve treatment outcomes by increasing the durability of brain changes, potentially reducing relapse rates in various psychological conditions.
Abstract
Abstract A leading theory for how psychedelics are able to produce robust clinical improvement and preclinical behavioral changes is that psychedel...
Effects of Serotonergic Psychedelics on Synaptic Function and Neuroplasticity
OPUS FAU - Online publication system of Friedrich-Alexander-Universität Erlangen-Nürnberg – January 01, 2026
Summary
Serotonergic psychedelics like LSD, psilocin, and DMT significantly inhibit neurotransmission, with notable effects on neuronal network activity. In a study using primary rat cortical cultures, psychedelics decreased synaptic vesicle fusion by up to 30% after 3-30 minutes of treatment. While DMT and psilocin enhanced responses at glutamatergic synapses, LSD and psilocin reduced presynaptic calcium transients. Additionally, LSD and DMT inhibited spontaneous neuronal firing without altering evoked responses. These findings deepen our understanding of how psychedelics could inform treatments for neuropsychiatric conditions.
Abstract
INTRODUCTION: Sertonergic psychedelics LSD, psilocin and DMT, have been shown to hold a great potential for treatment of various neuropsychiatric c...
Effects of Psilocin and Psilocybin on Human 5-HT4 Serotonin and H2 Histamine Receptors in Perfused Hearts of Transgenic Mice
Pharmaceuticals – July 06, 2025
Summary
The hallucinogen psilocybin dramatically boosts heart muscle contraction, increasing it by up to 152% in genetically modified hearts. This pharmacology insight reveals psilocybin and psilocin, a related psychedelic, enhance contraction by increasing phospholamban phosphorylation through the 5-HT4 serotonin receptor. This chemical mechanism, relevant to internal medicine and endocrinology, wasn't observed in wild-type hearts. Other alkaloids like ergotamine showed varied effects, highlighting complex neurotransmitter receptor influence on behavior. This work advances drug studies and our understanding of chemical synthesis.
Abstract
Background/Objectives: Hallucinogenic substances such as psilocybin, psilocin, ergometrine, ergotamine, and lysergic acid diethylamide (LSD) have b...
Microdosing Psychedelics: Current Evidence From Controlled Studies.
Biological psychiatry. Cognitive neuroscience and neuroimaging – May 01, 2024
Summary
Regular, tiny doses of lysergic acid diethylamide (LSD) can produce subtle but measurable effects on mood, pain perception, and social awareness without serious side effects. Controlled research shows that microdosing psychedelics at 10-20 micrograms affects blood pressure and brain connectivity while remaining safe. Lower doses of 5 micrograms showed no noticeable effects.
Abstract
Taking regular low doses of psychedelic drugs (microdosing) is a practice that has drawn recent scientific and media attention for its potential ps...
Hallucinogenic drugs attenuate the subjective response to alcohol in humans
Human Psychopharmacology Clinical and Experimental – January 01, 2000
Summary
A striking finding in Psychology and Pharmacology reveals that 86.7% of Lysergic acid diethylamide (LSD) users reported a complete blockade of alcohol's subjective effects when combined. Interviewing 22 users, another 60% of psilocybin users reported a partial antagonism. This suggests a significant interaction between alcohol and these hallucinogens. LSD's antagonism was notably stronger, possibly involving serotonergic receptor systems. These insights from Psychedelics and Drug Studies could inform future Medicine and Psychiatry approaches to addiction, particularly alcohol addiction.
Abstract
This study investigated possible interactions between alcohol and hallucinogens in 22 lysergic acid diethylamide (LSD) and/or psilocybin users thro...
Neurotoxic and Neuroprotective Effects of Psychedelics in a Human Neuroblastoma Cell Model
RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia – January 01, 2025
Summary
LSD exhibits the highest neurotoxicity among common psychedelics, significantly impacting neuroblastoma cells. In neuroscience drug studies on SH-SY5Y neuroblastoma cells, LSD showed EC50 values of 0.23 mM (mitochondrial) and 0.57 mM (lysosomal). Psilocin, an alkaloid, also displayed moderate cytotoxicity (0.42-0.69 mM). Conversely, psilocybin, 5-MeO-DMT, and mescaline were considerably less toxic. A neuroprotection study, involving five experiments, found limited protective effects against glutamate-induced damage.
Abstract
Psychedelic compounds, including psilocybin, psilocin, lysergic acid diethylamide (LSD), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), and mescalin...
Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland.
Psychiatry research – February 02, 2026
Summary
Significant improvements in Anxiety and Depression were observed in 115 adults undergoing Psychedelic-assisted psychotherapy with LSD or Psilocybin. This real-world analysis, involving 56.5% women, showed substantial reductions in depressive symptoms (effect size η²=0.42) and anxiety (η²=0.17) 1-3 months post-treatment. Patients receiving either 100 µg LSD or 25 mg psilocybin reported similar positive outcomes, alongside improved emotional regulation. The experience, potentially including mystical elements, was well-tolerated with mild, transient adverse events, highlighting the effectiveness of this approach.
Abstract
Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but real-world data from r...
Treatment of neuropathic pain with repeated low-dose MDMA: a case report.
Frontiers in psychiatry – January 01, 2025
Summary
A groundbreaking case shows how MDMA microdosing provided lasting relief for severe chronic pain. After traditional treatments failed, doctors explored psychedelic-assisted therapy, first with LSD then with MDMA. Small, repeated doses of MDMA significantly reduced the patient's neuropathic pain, with benefits persisting even after treatment ended. This suggests promising limited medical use for MDMA in pain management.
Abstract
A 64-year-old male patient who suffered from traumatic life experiences and neuropathic pain after oncological chemotherapy was treated with medium...
Magic of the Mushrooms: Effects of Psilocybin Decriminalization
Journal of Psychoactive Drugs – July 10, 2024
Summary
Decriminalization of psilocybin, a therapeutic hallucinogen, profoundly shifts public interest. Analysis of extensive web-based search data reveals a marked increase in psilocybin inquiries, alongside a notable reduction for other psychedelics like LSD and MDMA. This nationwide trend suggests a significant public health benefit, as individuals gravitate towards psilocybin, considered the safest option. This finding contributes to Psychedelics and Drug Studies, reflecting policy's impact on Medicine and Pharmacology, and its potential in Psychology for mental health.
Abstract
In the past few years, psilocybin, a psychedelic compound found in "magic mushrooms" (psilocybin mushrooms), has undergone decriminalization in num...
Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs).
Neuropharmacology – December 01, 2015
Summary
Many novel psychoactive substances, like NBOMe drugs, are chemically similar to phenethylamines but show surprisingly potent effects. This research meticulously mapped how these compounds bind to various brain receptors, revealing their high affinity for the 5-HT2A receptor, a key target for hallucinogens. The study found NBOMe drugs are exceptionally potent at this receptor, comparable to LSD, and also strongly interact with adrenergic α1 receptors. This unique receptor profile suggests powerful hallucinogenic effects, potentially coupled with stimulant properties.
Abstract
N-2-methoxybenzyl-phenethylamines (NBOMe drugs) are newly used psychoactive substances with poorly defined pharmacological properties. The aim of t...
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Journal of Psychopharmacology – May 14, 2019
Summary
Remarkably, 83% of individuals with alcohol use disorder (AUD) no longer met diagnostic criteria after naturalistic psychedelic use. An online survey of 343 respondents, 72% with severe AUD, indicated significant reductions in problematic alcohol consumption following experiences with substances like LSD (38%) or psilocybin (36%). Participants reported these highly meaningful psychedelic experiences, often involving higher doses, facilitated reduced alcohol misuse. This compelling psychology and clinical psychology data suggests a promising avenue for medicine and psychiatry in addressing alcohol consumption patterns, informing future drug studies.
Abstract
Background: Meta-analysis of randomized studies using lysergic acid diethylamide (LSD) for alcohol use disorder (AUD) showed large, significant eff...